

**Research Paper****Synthesis and Characterization of Benzothiazine Analogues**

**Gopiseti Jahnvi<sup>1</sup>, Amol Purushottam Kharche<sup>2</sup>, Mahammad Ishaq Beludari<sup>3</sup>,  
Praneetha Visampalli<sup>4</sup>, S. Savitha<sup>5</sup>, P. Mary<sup>6</sup> and Nayyar Parvez<sup>7\*</sup>**

<sup>1</sup>Department of Pharmaceutics, KVSRR siddhartha College of pharmaceutical sciences, Vijayawada. Andhra Pradesh 520008.

<sup>2</sup>Department of Applied Sciences and Humanities, Pimpri Chinchwad College of Engineering, Nigdi, Pune - 411044.

<sup>3</sup>Department of Pharmacy, College of applied sciences and Pharmacy, University of technology and applied sciences, Muscat, Oman.

<sup>4</sup>Pharmaceutical Chemistry Dept., KGRL college of Pharmacy, Bhimavaram, Andhra Pradesh.

<sup>5</sup>Department of chemistry, St. Joseph's college of engineering

<sup>6</sup>Department of pharmacology, School of pharmacy, Anurag university. Venkatapur (vi) Ghatkesar (M), Medchal (Dist), Hyderabad.Telangana-500088

<sup>7</sup>School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh.

**\*Corresponding author: Dr. Nayyar Parvez, School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh. E-mail: [nparvez2013@gmail.com](mailto:nparvez2013@gmail.com)**

**ABSTRACT:**

Benzene joins a 1,4-thiazine ring to form benzothiazines, an important group of heterocycles. As part of our ongoing research into new ways to make molecules that have biological effects, we were interested in making different heterocyclic structures with thiazine rings. This is due to the fact that heterocyclic structures are a necessary component of many physiologically active, naturally occurring compounds. We have created a quick, solvent-free synthesis technique for the oxidative cyclo condensation of 2-amino benzenethiol and 1, 3-dicarbonyl using a catalytic quantity of hydrazine hydrate. In order to generate a high yield of 2,3-disubstituted-1,4-benzothiazines, this technique was developed.


**Keywords:** Synthesis, Benzothiazine, 2-aminobenzenethiol, 4H-1, 4-Benzothiazines.

**INTRODUCTION:**

Medicinal chemistry is very interested in benzothiazine analogues because they have many biological effects, such as antibacterial, anti-inflammatory, anticancer, and antioxidant effects (1). There is only one benzothiazine ring system in the world. It is made up of a benzene ring fused with a thiazine ring. This gives it special chemical and biological properties.




Throughout the years, alterations to this fundamental structure have resulted in the creation of several derivatives with improved pharmacological properties (2). We must purposefully alter the core structure to create benzothiazine analogues. These changes can be made through nucleophilic substitution, cyclization, or oxidation. We plan how to make these compounds so that they have the highest yield and selectivity, and we add functional groups that make them more bioactive (3). When people make new benzothiazine derivatives, they often want to improve their solubility, stability, and target specificity, all of which are important for making medicines that work well (4). Characterizing benzothiazine analogues is an important part of the development process because it gives information about the molecules' structure, purity, and physical properties. An NMR spectrometer, an MS spectrometer, an IR spectrometer, and an X-ray crystallography are some of the tools that are used to look at the molecular structure and chemical integrity of substances (5). High-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC) are also often used to check for purity and find byproducts made during synthesis. We must make benzothiazine-derived compounds efficiently and thoroughly characterize them for medical use (6). This project investigated how to make new benzothiazine analogues and characterized them by checking their chemical and structural properties and considering their medical uses (7).



1,4-Benzothiazine derivatives have many medical and biological effects, such as killing fungi, boosting the immune system, treating rheumatism and other rheumatic conditions, relaxing blood vessels, blocking aldose reductase, stopping irregular heartbeats, protecting neurons, killing parasites and bacteria, fighting viruses and bacteria, lowering blood pressure, reducing inflammation, fighting depression, fighting tumors, lowering fever, increasing urine production, and fighting tuberculosis— all of these and more (8, 9). The properties imply that 1,4-benzothiazine is a viable template for therapeutic applications and medicinal chemistry. Dyes and photography use 1,4-derivatives of benzothiazine. Their typical preparation process involves the use of either expensive and dangerous solvents or lachrymatory halo organic substrates (10). Our main goal is to come up with a safe and long-lasting way to make 4H-1,4-benzothiazine derivatives, keeping in mind the different ways that these bioactive thiazine derivatives can be used. Many researchers have reported the synthesis of 4H-1,4-




benzothiazine with the aid of microwaves (11). It is possible to make 1,4-benzothiazines by mixing 2-aminobenzene thiol with ethyl 2-chloroacetoacetate in ethanol (12).



**Figure 1:** Synthesis of 4H-1,4-Benzothiazines

A rapid, solvent-free synthesis technique for the oxidative cyclo-condensation of 2-amino benzenethiol and 1,3-dicarbonyl using a catalytic quantity of hydrazine hydrate has been developed in order to create 2,3-disubstituted-1,4-benzothiazines in high yield (figure 2) (13, 14)



**Figure 2:** 2, 3-disubstituted-1,4-benzothiazines

Typically, 2-aminobenzene thiol reacted with  $\alpha$ -haloketones or  $\alpha$ -haloesters to create 1,4-benzothiazines; however, the primary disadvantage of this process was the lachrymatory nature of the latter (15). The process for producing 1, 4-benzo-thiazines has been marginally enhanced in recent years. In the presence of DMSO, substituted 2-amino benzene thiol




undergoes oxidative condensation with  $\beta$ -diketones and  $\beta$ -ketoesters (16, 17). The latter has both solvent and oxidant qualities and is a dipolar aprotic solvent. It contains several negative features, and it is difficult to separate the product from it. Therefore, this strategy needs to be improved (18). The mechanism of the reaction between  $\beta$ -diketones/ $\beta$ -ketoesters and substituted 2-aminobenzenethiols involves two stages (19). First, 2-aminobenzenethiols are oxidized by DMSO to their corresponding disulfide derivatives, which then condense with  $\beta$ -diketones and  $\beta$ -keto esters to produce 4H-1, 4-benzothiazines in the second phase. According to the literature review, 2-aminobenzenethiols are readily oxidized by hydrogen peroxide, sodium perborate, thallium acetate, DMSO-iodine, a combination of  $\text{NO}_2$  and  $\text{NO}_3$ , and even ambient oxygen when left in the presence of a little quantity of base (20-28).

#### **MATERIAL AND METHODS:**

The reactions were conducted in a household microwave oven. All the analytical and physical data for the synthesized substances align well with their literature values (29).

##### **Synthesis of substituted 4H-1, 4-benzothiazines**

DMF (5 mmol), catalytic hydrazine hydrate (1 mmol), and substituted 2-amino benzenethiol (10 mmol) were mixed together and put through microwaves for 30 seconds. After adding 10 mmol of  $\beta$ -diketone to the reaction mixture, it is microwaved again and again for three minutes, with breaks of thirty seconds (30-38). After monitoring the reaction's conclusion with TLC, we cooled the reaction mixture and placed it on crushed ice. After filtering and washing with 50% ethanol, the isolated material crystallized from the ethanol (Figure 3) (39, 52).



**Figure 3:** Synthetic scheme of 1, 4-benzothiazines analogues

## RESULT AND DISCUSSION:

In present investigation following 1, 4-benzothiazines analogues have been synthesized:

**Table 1:** Physical data of the synthesized benzothiazines derivatives

Sr. No	Name	Structure	MP	Mol Formula	Yield
1	7-Ethoxy-2-ethoxycarbonyl-3-methyl-4H-1,4-benzothiazine		103 <sup>0</sup> C	C <sub>14</sub> H <sub>17</sub> O <sub>3</sub> NS	70%
2	2-Ethoxycarbonyl-7-methoxy-3-methyl-4H-1,4-benzothiazine		119 <sup>0</sup> C	C <sub>13</sub> H <sub>15</sub> O <sub>3</sub> NS	65%



3	2-Benzoyl-7-methoxy-3-phenyl-4H-1,4-benzothiazine		172 <sup>0</sup> C	C <sub>22</sub> H <sub>17</sub> O <sub>2</sub> NS	82%
4	2-Ethoxycarbonyl-3,7-dimethyl-4H-1,4-benzothiazine		178 <sup>0</sup> C	C <sub>13</sub> H <sub>15</sub> O <sub>2</sub> NS	75%
5	2-Benzoyl-7-methyl-3-phenyl-4H-1,4-benzothiazine		194 <sup>0</sup> C	C <sub>22</sub> H <sub>17</sub> ONS	80%
6	7-Chloro-2-ethoxycarbonyl-3-methyl-4H-1,4-benzothiazine		181 <sup>0</sup> C	C <sub>12</sub> H <sub>12</sub> O <sub>2</sub> NSCl	75%
7	2-Benzoyl-7-chloro-3-phenyl-4H-1,4-benzothiazine		87 <sup>0</sup> C	C <sub>21</sub> H <sub>14</sub> ONSCl	85%
8	2-Benzoyl-7-chloro-3-methyl-4H-1,4-benzothiazine		245 <sup>0</sup> C	C <sub>16</sub> H <sub>12</sub> ONSCl	85%



9	2-Benzoyl-3,7-dimethyl-4H-1,4-benzothiazine		207 <sup>0</sup> C	C <sub>17</sub> H <sub>15</sub> ONS	90%
---	---	--	--------------------	-------------------------------------	-----

**Table 2:** Analytical data of the synthesized benzothiazines derivatives

Mol No	IR	NMR	Mass
1	IR (KBr, $\nu_{\max}$ , cm <sup>-1</sup> ): 3410(N-H), 1685 (>C=O), 1460, 1350(C-CH <sub>3</sub> ), 1230, 1035(C-O-C), 855, 835 (adj.2H in ring), 3000 (C-Haliph.)	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ : 6.85-6.3 (3H, m, Ar.), 4.10(2H, q, CH <sub>2</sub> a tC-2), 1.20(3H, t, CH <sub>3</sub> at C-2), 2.2 (3H, s, CH <sub>3</sub> at C-3), 3.95(2H, q, CH <sub>2</sub> at C-7), 1.40 (3H, t, CH <sub>3</sub> at C-7), 8.75 (1H, s, N-H)	MS (m/z): 279 (M <sup>+</sup> ), 278 (M <sup>+</sup> -H), 251(M <sup>+</sup> -C <sub>2</sub> H <sub>4</sub> ), 250 (M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> ), 233 (M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> OH), 234 (M <sup>+</sup> -OC <sub>2</sub> H <sub>5</sub> ), 222 (M <sup>+</sup> -COC <sub>2</sub> H <sub>5</sub> ), 205 (M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> OH, CO). Anal. Calculated (%) for C <sub>14</sub> H <sub>17</sub> O <sub>3</sub> NS: C, 60.21; H, 6.09; N, 5.01.Found (%): C, 60.11; H, 6.08; N, 5.02.
2	IR (KBr, $\nu_{\max}$ , cm <sup>-1</sup> ):3340(N-H), 1685(>C=O), 1465, 1340(C-CH <sub>3</sub> ), 1245, 1035(C-O-C), 850, 820 (adj.2Hin ring)	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ : 6.8-6.4 (3H, m, Ar.), 3.95(2H, q, CH <sub>2</sub> at C-2), 2.25 (3H, s, CH <sub>3</sub> at C-3), 1.25(3H, t, CH <sub>3</sub> at C-2), 4.4(3H, s,O-CH <sub>3</sub> ), 8.8(1H,s,N-H)	MS (m/z): 265(M <sup>+</sup> ), 264(M <sup>+</sup> -H), 235(M <sup>+</sup> -CH <sub>2</sub> O), 206(M <sup>+</sup> -CH <sub>2</sub> O, C <sub>2</sub> H <sub>5</sub> ), 178 (M <sup>+</sup> -CH <sub>2</sub> O, COC <sub>2</sub> H <sub>5</sub> ), 250(M <sup>+</sup> -CH <sub>3</sub> ), 222(M <sup>+</sup> -CH <sub>3</sub> , CO), 193(M <sup>+</sup> -CH <sub>3</sub> , CO, C <sub>2</sub> H <sub>5</sub> ), 165(M <sup>+</sup> -CH <sub>3</sub> , CO, COC <sub>2</sub> H <sub>5</sub> ). Anal. Calculated (%) for: C <sub>13</sub> H <sub>15</sub> O <sub>3</sub> NS: C, 58.86; H, 5.66; N, 5.28. Found (%): C, 58.84; H, 5.67; N, 5.30.
3	IR (KBr, $\nu_{\max}$ , cm <sup>-1</sup> ): 3400(N-H), 1665 (>C=O), 1230, 1050(C-O-C), 855, 820 (adj.2H in ring), 2920(C-	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ : 7.8-6.95 (13H, m, Ar.), 4.5 (3H, s, OCH <sub>3</sub> ), 8.7 (1H, s, N-H)	MS (m/z): 359(M <sup>+</sup> ), 358(M <sup>+</sup> -H), 254(M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> ), 282(M <sup>+</sup> -C <sub>6</sub> H <sub>5</sub> ), 329(M <sup>+</sup> -CH <sub>2</sub> O), 344 (M <sup>+</sup> -CH <sub>3</sub> ), 316 (M <sup>+</sup> -CH <sub>3</sub> , CO), 252(M <sup>+</sup> -CH <sub>2</sub> O, C <sub>6</sub> H <sub>5</sub> ), 224 (M <sup>+</sup> -CH <sub>2</sub> O, COC <sub>6</sub> H <sub>5</sub> ). Anal.



	H,aliph.)		Calculated (%) for C <sub>22</sub> H <sub>17</sub> O <sub>2</sub> NS: C, 70.19; H, 4.73; N, 3.90. Found (%): C, 70.20; H, 4.69; N, 3.88.
4	IR (KBr, $\nu_{\max}$ , cm <sup>-1</sup> ): 3460 (N-H), 1680 (>C=O), 1465, 1345 (C-CH <sub>3</sub> ), 1230, 1035 (C-O-C), 855, 825 (adj. 2H in ring), 2980 (C-H aliph.)	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ : 6.7-6.4 (3H, m, Ar.), 4.15 (2H, q, CH <sub>2</sub> at C-2), 2.25 (3H, s, CH <sub>3</sub> at C-3), 1.95 (3H, s, CH <sub>3</sub> at C-7), 1.25 (3H, t, CH <sub>3</sub> at C-2), 8.8 (1H, s, N-H)	MS (m/z): 249(M <sup>+</sup> ), 248(M <sup>+</sup> -H), 220 (M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> ), 204(M <sup>+</sup> -OC <sub>2</sub> H <sub>5</sub> ), 192(M <sup>+</sup> -COC <sub>2</sub> H <sub>5</sub> ), 221 (M <sup>+</sup> -C <sub>2</sub> H <sub>4</sub> ), 203(M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> OH), 175(M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> OH, CO). Anal. Calculated (%) for C <sub>13</sub> H <sub>15</sub> O <sub>2</sub> NS: C, 62.65; H, 6.02; N, 5.62. Found (%): C, 62.63; H, 6.63; N, 5.60
5	IR (KBr, $\nu_{\max}$ , cm <sup>-1</sup> ): 3345 (N-H), 1695 (>C=O), 1470, 1330 (C-CH <sub>3</sub> ), 865, 820 (adj. 2H in ring), 3055 (C-H, Ar)	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ : 7.3-7.0 (13H, m, Ar.), 2.35 (3H, s, CH <sub>3</sub> at C-7), 8.8 (1H, s, NH)	MS (m/z): 343 (M <sup>+</sup> ), 342 (M <sup>+</sup> -H), 238 (M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> ), 266 (M <sup>+</sup> -C <sub>6</sub> H <sub>5</sub> ), 161(M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> , C <sub>6</sub> H <sub>5</sub> ). Anal. Calculated (%) for C <sub>22</sub> H <sub>17</sub> ONS: C, 73.46; H, 4.95; N, 4.08. Found (%): C, 73.75; H, 4.90; N, 4.06
6	IR (KBr, $\nu_{\max}$ , cm <sup>-1</sup> ): 3380 (N-H), 1690 (>C=O), 1465, 1360 (C-CH <sub>3</sub> ), 735 (C-Cl), 1240, 1040 (C-O-C), 860,825 (adj. 2H in ring), 2985 (C-H aliph.)	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ : 6.85-6.4 (3H, m, Ar.), 4.05 (2H, q, CH <sub>2</sub> at C-2), 2.25 (3H, s, CH <sub>3</sub> at C-3), 1.25 (3H, t, CH <sub>3</sub> at C-2), 8.7 (1H, s, N-H)	MS (m/z): 269 (M <sup>+</sup> ), 268 (M <sup>+</sup> -H), 241 (M <sup>+</sup> -C <sub>2</sub> H <sub>4</sub> ), 224 (M <sup>+</sup> -C <sub>2</sub> H <sub>4</sub> , OH) or (M <sup>+</sup> -OC <sub>2</sub> H <sub>5</sub> ), 196 (M <sup>+</sup> -COOC <sub>2</sub> H <sub>5</sub> ), 240 (M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> ), 223 (M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> OH), 212(M <sup>+</sup> -C <sub>2</sub> H <sub>5</sub> , CO). Anal. Calculated (%) for C <sub>12</sub> H <sub>12</sub> O <sub>2</sub> NSCl: C, 53.43; H, 4.45; N, 5.19. Found (%): C, 53.39; H, 4.42; N, 5.20
7	IR (KBr, $\nu_{\max}$ , cm <sup>-1</sup> ):	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ :	MS (m/z): 363 (M <sup>+</sup> ), 362 (M <sup>+</sup> -





	3360 (N-H), 1690 (>C=O), 740 (C-Cl), 850, 820 (adj.2H in ring), 3060 (C-H, Ar)	7.5-6.85 (13H, m, Ar), 8.6 (H, s, N-H)	H), 258 (M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> ), 286 (M <sup>+</sup> -C <sub>6</sub> H <sub>5</sub> ), 77 (M <sup>+</sup> -C <sub>6</sub> H <sub>5</sub> ), 181 (M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> , C <sub>6</sub> H <sub>5</sub> ), 146 (M <sup>+</sup> - COC <sub>6</sub> H <sub>5</sub> , C <sub>6</sub> H <sub>5</sub> , Cl) Anal. Calculated (%) for C <sub>21</sub> H <sub>14</sub> ONSCl: C, 69.32; H, 3.85; N, 3.85. Found (%): C, 69.30; H, 3.90; N, 3.90
8	IR (KBr, $\nu_{\max}$ , cm <sup>-1</sup> ): 3365 (N-H), 1675 (>C=O), 1460, 1340 (C-CH <sub>3</sub> ), 725 (C-Cl), 850, 830 (adj. 2H in ring), 3020 (C-H, Ar)	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ : 7.6-7.0 (8H, m, Ar.), 2.25 (3H, s, CH <sub>3</sub> at C- 3), 8.7 (1H, s, NH)	MS (m/z): 301 (M <sup>+</sup> ), 300 (M <sup>+</sup> - H), 196 (M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> ), 224(M <sup>+</sup> - C <sub>6</sub> H <sub>5</sub> ), 161 (M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> , Cl). Anal. Calculated (%) for: C <sub>16</sub> H <sub>12</sub> ONSCl: C, 59.70; H, 4.97; N, 4.64. Found (%): C, 59.68; H, 4.89; N, 4.60
9	IR (KBr $\nu_{\max}$ , cm <sup>-1</sup> ): 3380 (N-H), 1680 (>C=O), 1460, 1340 (C-CH <sub>3</sub> ), 860, 825 (adj. 2H in ring), 2930 (C-H, aliph.), 3030 (C-H, Ar.)	<sup>1</sup> HNMR (CDCl <sub>3</sub> ) $\delta$ : 7.4-6.6 (8H, m, Ar.), 2.15 (3H, s, CH <sub>3</sub> at C- 3), 1.95 (3H, s, CH <sub>3</sub> at C-7), 8.8 (1H, s, NH)	MS (m/z): 281 (M <sup>+</sup> ), 280 (M <sup>+</sup> - H), 204 (M <sup>+</sup> -C <sub>6</sub> H <sub>5</sub> ), 176 (M <sup>+</sup> - COC <sub>6</sub> H <sub>5</sub> ), 131 (M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> , HCS), 144 (M <sup>+</sup> -COC <sub>6</sub> H <sub>5</sub> , S). Anal. Calculated (%) for C <sub>17</sub> H <sub>15</sub> ONS: C, 72.59; H, 5.33; N, 4.98. Found (%): C, 72.60; H, 5.35; N, 4.95.

### Spectral analysis

The IR spectra of the different synthesized 1,4-benzothiazines were all different. The C=O stretching absorption peak was found between 1695 and 1665 cm<sup>-3</sup>, and the N-H stretching absorption peak was between 3410 and 3340 cm<sup>-3</sup>. Bending vibrations of C-CH cause the weak absorption bands in the 1470–1330 cm range. Between 1240 and 1225 cm<sup>-3</sup> and 1030 to 1040 cm<sup>-3</sup> are the bands that show up in compounds 1, 2, 4, and 6. Asymmetric and symmetric C-O-C vibrations, respectively, cause these bands. A band in the range of 725-740 cm<sup>-1</sup> is attributed to C-Cl stretching vibrations in compounds 6, 7, and 8. The NMR spectra of



all the compounds show a single broad peak for the N-H proton between 8.70 and 8.80. Protons in the aromatic ring trigger multiplets in the 6.4–7.6 area. Methoxy derivatives have a singlet peak at around 4.4 $\delta$  because of the OOCCH<sub>3</sub> group. The multiplicity and anticipated region also show peaks for the C<sub>2</sub>H<sub>5</sub> and CH<sub>3</sub> groups. The mass spectra of all 1,4-benzothiazines with a benzoyl group had a peak at  $m/z = M+105$  (with high intensity) and 105 (C<sub>6</sub>H<sub>5</sub>CO<sup>+</sup> base peak) because the benzoyl group was gone. Peaks were found at  $m/z = M+M-C_2H_4$ ,  $M+M-C_2H_5$ ,  $M+M-COC_2H_5$  and  $M+M-OC_2H_5$  or the 2-ethoxycarbonyl derivatives.

### CONCLUSION:

A 1,4-thiazine ring fused to benzene characterizes benzothiazines, a heterocycle class. We were interested in synthesizing heterocyclic thiazine rings as part of an effort to discover novel synthetic methods for physiologically active compounds. This is because heterocyclic structures are essential to many physiologically active natural substances. We made a quick and easy oxidative cyclo condensation method for 2-amino benzenethiol and 1, 3-dicarbonyl with hydrazine hydrate as a catalyst. We devised this method to produce 2, 3-disubstituted-1,4-benzothiazines in high yield. Different synthesized 4H-1, 4-benzothiazines had different infrared spectra. The C=O and N-H stretching absorption peaks were observed between 1695 and 1665 cm<sup>-1</sup> and 3410 and 3340 cm<sup>-1</sup>, respectively. The weak absorption bands in the 1470-1330 cm<sup>-1</sup> range result from C-CH<sub>3</sub> bending vibrations. Compounds 1, 2, 4, and 6 exhibit bands in the 1240–1225 cm and 1030–1040 cm ranges. These are caused by asymmetric and symmetric C–O–C vibrations. A band at 725-740 cm<sup>-1</sup> is attributed to C-Cl stretching vibrations in compounds 6, 7, and 8. The NMR spectra of all compounds exhibit a large singlet peak for the N-H proton, around 8.70–88.80. Rotons in the aromatic ring create 6.4–7.6 multiplets. Methoxy derivatives have a singlet peak at 4.4 $\delta$  due to the OOCCH<sub>3</sub> group. Both C<sub>2</sub>H<sub>5</sub> and CH<sub>3</sub> groups have peaks in the multiplicity and expected region. Because they were missing a group, all 1, 4-benzothiazines with a benzoyl group in their mass spectra had a peak at  $m/z = M+105$  (high intensity) and 105 (C<sub>6</sub>H<sub>5</sub>CO<sup>+</sup> base peak). Peaks were seen at  $m/z = M+M-C_2H_4$ ,  $M+M-C_2H_5$ , and  $M+M-OC_2H_5$ , or 2-ethoxycarbonyl derivatives.

### DISCLOSURE STATEMENT:

There is no conflict of interest financial or otherwise.

### ADDITIONAL INFORMATION

### FUNDING:



This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## REFERENCES:

1. Tiwari, G., Gupta, M., Devhare, L. D., & Tiwari, R. (2024). Therapeutic and phytochemical properties of thymoquinone derived from *Nigella sativa*. *Current Drug Research Reviews Formerly: Current Drug Abuse Reviews*, 16(2), 145-156.
2. Mostafa, M. S., Radini, I. A. M., El-Rahman, N. M. A., & Khidre, R. E. (2024). Synthetic Methods and Pharmacological Potentials of Triazolothiadiazines: A Review. *Molecules*, 29(6), 1326.
3. Tiwari, R., Khatri, C., Tyagi, L. K., & Tiwari, G. (2024). Expanded Therapeutic Applications of *Holarrhena Antidysenterica*: A Review. *Combinatorial Chemistry & High Throughput Screening*, 27(9), 1257-1275.
4. Dincel, E. D., & Güzeldemirci, N. U. (2019). Discovery, Synthesis and Activity Evaluation of Novel Compounds Bearing 1, 2, 4-triazolo [3, 4-b][1, 3, 4] thiadiazine Moiety: A Review. *Sağlık Bilimlerinde İleri Araştırmalar Dergisi*, 2(2), 60-70.
5. Tiwari, G., Tiwari, R., & Kaur, A. (2023). Pharmaceutical Considerations of Translabial Formulations for Treatment of Parkinson's Disease: A Concept of Drug Delivery for Unconscious Patients. *Current Drug Delivery*, 20(8), 1163-1175.
6. Tiwari, R., Tiwari, G., & Parashar, P. (2023). Theranostics Applications of Functionalized Magnetic Nanoparticles. In *Multifunctional And Targeted Theranostic Nanomedicines: Formulation, Design And Applications* (pp. 361-382). Singapore: Springer Nature Singapore.
7. Tiwari, R., Tiwari, G., Mishra, S., & Ramachandran, V. (2023). Preventive and therapeutic aspects of migraine for patient care: An insight. *Current Molecular Pharmacology*, 16(2), 147-160.
8. Boraie, A. T., Ghabbour, H. A., Gomaa, M. S., El Ashry, E. S. H., & Barakat, A. (2019). Synthesis and anti-proliferative assessment of triazolo-thiadiazepine and triazolo-thiadiazine scaffolds. *Molecules*, 24(24), 4471.
9. Tiwari, R., & Pathak, K. (2023). Local drug delivery strategies towards wound healing. *Pharmaceutics*, 15(2), 634.
10. Tiwari, R., Tiwari, G., Sharma, S., & Ramachandran, V. (2023). An Exploration of herbal extracts loaded phyto-phospholipid complexes (Phytosomes) against polycystic ovarian syndrome: Formulation considerations. *Pharmaceutical Nanotechnology*, 11(1), 44-55.
11. Tiwari, G., Chauhan, A., Sharma, P., & Tiwari, R. (2022). Nutritional Values and



Therapeutic Uses of *Capra hircus* Milk. International Journal of Pharmaceutical Investigation, 12(4).

12. Kaushik, D., Sardana, S., & Mishra, D. N. (2009). 5-fluorouracil loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro release. Yao xue xue bao= Acta pharmaceutica Sinica, 44(11), 1278-1284.

13. Deep, A., Kaur Bhatia, R., Kaur, R., Kumar, S., Kumar Jain, U., Singh, H., ... & Kishore Deb, P. (2017). Imidazo [1, 2-a] pyridine scaffold as prospective therapeutic agents. Current topics in medicinal chemistry, 17(2), 238-250.

14. Dincel, E. D., Akdağ, Ç., Kayra, T., Coşar, E. D., Aksoy, M. O., Akalın-Çiftçi, G., & Ulusoy-Güzeldemirci, N. (2022). Design, synthesis, characterization, molecular docking studies and anticancer activity evaluation of novel hydrazinecarbothioamide, 1, 2, 4-triazole-3-thione, 4-thiazolidinone and 1, 3, 4-oxadiazole derivatives. Journal of Molecular Structure, 1268, 133710.

15. Jyoti, K., Pandey, R. S., Kush, P., Kaushik, D., Jain, U. K., & Madan, J. (2017). Inhalable bioresponsive chitosan microspheres of doxorubicin and soluble curcumin augmented drug delivery in lung cancer cells. International journal of biological macromolecules, 98, 50-58.

16. Kaushik, D., Sardana, S., & Mishra, D. N. (2009). In vitro cytotoxicity analysis of 5-fluorouracil loaded guar gum microspheres on HT-29 colon cancer cell line. Int J Pharm Sci Drug Res, 1(2), 83-4.

17. Indora, N., & Kaushik, D. (2015). Design, development and evaluation of ethosomal gel of fluconazole for topical fungal infection. International journal of engineering science invention research & development, 1(8), 280-306.

18. Kaushik, D., Kumar, P., & Sardana, S. (2015). Design development and evaluation of nanosuspension of azithromycin. International Journal of Pharmaceutical Sciences and Drug Research, 7(5), 384-394.

19. Kaushik, D., Malik, J., & Sardana, S. Formulation and Evaluation of Self Nanoemulsifying Drug Delivery System of Nifedipine.

20. Kaushik, D., Sharma, K., & Sardana, S. (2016). Colon targeting guar gum microspheres of 5-aminosalicylic acid: evaluation of various process variables, characterization and in-vitro drug release. Cell, 91, 130-2221072.

21. Pippalla, S., Kumar, V., Nekkalapudi, A.R.(2024). A Novel, Stability-Indicating RP-HPLC Method for Simultaneous Estimation of Assay and Organic Impurities of Pyridostigmine Bromide and Assay of Sodium Benzoate in Liquid Oral Formulation. Pharm Chem J 58, 1339–1347.



22. Sreenivas Pippalla, Arjuna Rao Nekkalapudi, Suresh Babu Jillellamudi .(2022).Stability Indicating RP-UPLC Method for Quantification of Glycopyrrolate, Methylparaben and Propylparaben Assay in Liquid Oral Formulation American Journal of Analytical Chemistry 13(12).
23. Pippalla S, Nekkalapudi AR, Jillellamudi SB, Reddy MP, Kumar CV.(2023) A stability-indicating, reversed-phase HPLC method for quantification of assay and organic impurities in doxycycline hyclate bulk and parenteral dosage forms. Biomed Chromatogr. 2023 Mar 17: e5626.
24. Sreenivas Pippalla, Arjuna Rao Nekkalapudi, Venugopal Reddy Komreddy.(2024).A validated stability-indicating reversed-phase-UPLC method for simultaneous estimation of promethazine hydrochloride, methylparaben, propylparaben and sodium benzoate assay of cough suppressant and antihistamine liquid oral dosage forms. Biomed Chromatogr. 2024 July14: e5944.
25. Sreenivas Pippalla, Srinivasulu Kasa, Dipak Goyal, Venugopal Komreddy, Poluri Venkata Reddy.(2024).A Novel Reversed Phase HPLC Assay Method for Simultaneous Estimation of Glucose, Sodium Citrate and Chlorides in Pharmaceutical Formulations and Drug Solution for Oral Rehydration. Journal of Pharmaceutical, Research & Reports. SRC/IPRSR-180.
- 26.Gaurav Tiwari, Santosh Karajgi, Vattakkalvalasu Ramathan Ravikkumar, Ram Kumar Choudhary, Jegannathan Kannan Shyamala, Vinod Kumar, Sreenivas Pippalla.(2024).An In-depth Review of Exploring the Potential of Colloidosomes in Drug Delivery.International Journal of Pharmaceutical Investigation 14 (4).
27. Arjuna Rao Nekkalapudi, Srinivasu Navuluri, Sreenivas Pippalla.(2024).Eco-Friendly Stability-Indicating HPLC Method for Related Compounds in Pemetrexed Ditromethamine (Antineoplastic Agent) for Injection.Journal of AOAC INTERNATIONAL, Volume 107, Issue 3, May-June 2024, Pages 415–429.
28. Dr Dinesh Kaushik, Madhu (2021). Design And Development Of Curcumin Loaded Nanoparticles For Antibacterial Activity in Journal of Emerging Technologies and Innovative Research, December 2021, volume 8, Issue 12, pages 165-181.
29. Vivek Atri, Dinesh Kaushik, Bharat Bhushan, (2023),Design Development and Evaluation of Tenoxicam microsphere as gel in IJPRA, volume 8, Issue 1, pages 1988-2011.
30. Pankaj Kumar, Dinesh Kaushik, Bharat Bhushan, (2022), A Descriptive review on vasicular drug delivery system: Sphingosomes in BJPMR, volume 7, Issue 5, pages 4031-4043.



31. Dr. Dinesh Kaushik Sanju Rani, Dr. Arjun Kumar(2024), Optimization , formulation and evaluation of fast disintegrating tablet of meloxicam in IJCRT, volume 12, Issue 2, pages 962-998.
32. Shivani Sharma, Dinesh Kaushik(2023), Cefuroxime Axetil : An oral prodrug of cefuroxime sodium. In AJPT, volume 13, Issue 4.
33. Dr. Dinesh Kaushik, Manisha, Dr. Saroj Jain(2024), Fast dissolving tablets of Nano-Steroids Anti- Inflammatory drug: A review in IJRTI, volume 9, Issue 3, pages 706-720.
34. Gourav, Dinesh Kaushik, Saroj Jain(2022), SNEDDS: A vital role in Drug Delivery true or myth in WJPER, volume 11, Issue 13, pages 1965-1991.
35. Arman Dalal, Dinesh Kaushik, Saroj jain (2022), Invasomes : A novel deformable vasicluar nanocarrier for enhanced transdermal drug delivery in BJPMR, volume 7, Issue 5, pages 4044-4059.
36. Dinesh Kaushik, Satish Sardana, D.N Mishra(2010) In vitro characterization and Cytotoxicity analysis of 5-Flurouracil loaded chitosan Microspheres for Targeting colon cancer in Indian J Pharma. Education and Research, Volume44, Issue 1.
37. Dinesh Kaushik, Sandhya, Devender Chauhan(2022) Ligand Decorated nanoparticles of Colchicine for targeting Breast cancer cells in WJPR, volume 11, Issue 1, pages 1839-1858.
38. Iqar Ali Alvi, Jitender Madan, Dinesh Kaushik, Satish Sardana, Ravi Shankar Pandey, Asgar Ali (2011), Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis in Anti-cancer drugs journal, volume 22, Issue 8, pages 774-782.
39. Dinesh Kaushik, Satish Sardana, DN Mishra (2009), 5-fluorouracil loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro release, volume 44, Issue 11, pages 1278-1284.
40. Preeti Nashier, Kavita Berwar, Dinesh Kaushik, Bharat Bhushan (2022), A Concise Review On Designing Of Dosage Forms in World Journal of pharmaceutical research, volume 11, Issue 16, pages 198-225.
41. Vivek, Dinesh Kaushik (2019), A review article on Silver nanoparticle: An Emerging technology in drug delivery review in EJPMR, volume 6, Issue 7, pages 583-591.
42. Satish Sardana Dinesh Kaushik, Jyoti Malik (2015), Formulation and Evaluation of Self Nanoemulsifying Drug Delivery System of Nifedipine in International Journal of Drug Delivery Technology, volume 5, issue 4.
43. Shivani Sharma, Dinesh Kaushik(2023), To study the molecular docking of Omicron variant with several anti microbial drugs using autoDOCK tools in IAJPR, volume 13, issue





6, pages 940-966.

44. Bharat Bhushan Pankaj Kumar, Dinesh Kaushik(2022), A Descriptive review on vasicular drug delivery system: Sphingosomes in BJPMR, volume 7, issue 5, Pages 4031-4043.

45. Arman Dalal, Dinesh Kaushik, Saroj Jain(2022), Invasomes: A Novel Deformable Vesicular Nanocarrier For Enhanced Transdermal Drug Delivery in British Journal of Pharmaceutical and Medical Research, volume 7, issue 5, pages 4044-4059.

46. Tharmaraj Vairaperumal,a Dhakshnamoorthy Vellingiri,b P.K. Hemalatha,c Kuppusamy Kanagarajc,\* Book Project: 3D Printing of Carbon-based Materials (Publisher: Elsevier/ELSA) 2.3D Printing of Carbon-Based Materials Applications in Architecture and Construction (Invited on Elsevier/ELSA).

47. Dhakshnamoorthy Vellingiri, Book Project: Biosynthesis Of Polyhydroxyalkanoates (Pha): Technology, Environment & Sustainability (Publishers: Wiley Scrivener)

48. Kalimuthu Karuppanan,a Kannan Raman,b Dhakshnamoorthy Vellingiri,c Jeevithan Elango,d Kuppusamy Kanagaraje,\*Innovative Biosynthesis of Polyhydroxyalkanoates (PHA) for Upcoming Generations (new title in place of “Challenges, Opportunities and Future Trends of Biosynthesis of Polyhydroxyalkanoates (PHA)” to avoid duplication).

49.Exploring the Potential of Gastro Retentive Drug Delivery Systems: An Insightful Perspective RT Saket Mishra, Priyanka Shukla, Deshraj Shyamkant Chumbhale, Pijush. International Journal of Pharmaceutical Investigation 15 (3), 1-22, 2025.

50.Fagnidi YKH, Ziki E, Gabin Allangba KNP, Toï B, Megnassan E. Structure-based design of novel Pyrimidine carbonitriles analogs targeting the Cysteine protease Falcipain 2 of Plasmodium falciparum(pfFP2) at the trophozoïte stage with favorable ADME specificities.Universal Journal of Pharmaceutical Research 2023; 8(5):39-52.<https://doi.org/10.22270/ujpr.v8i5.1008>

51.Kapoor K. Coumarin analogues as a potential inhibitor of leishmaniasis: a multi-targeting protein inhibition approach by molecular docking.Universal Journal of Pharmaceutical Research 2019; 4(3): 6-10.<https://doi.org/10.22270/ujpr.v4i3.268>

52. Soro I, N’Guessan H, Abou A, N’Guessan RK, Megnassan E. Conformational study of molecules in a biological environment, design of inhibitors of human aminopeptidase M1 implicated in cancertherapy.Universal Journal of Pharmaceutical Research 2023; 8(5):71-86. <https://doi.org/10.22270/ujpr.v8i5.1011>